E. ELİAÇIK Et Al. , "Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms," TURKISH JOURNAL OF HEMATOLOGY , vol.32, no.2, pp.163-167, 2015
ELİAÇIK, E. Et Al. 2015. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms. TURKISH JOURNAL OF HEMATOLOGY , vol.32, no.2 , 163-167.
ELİAÇIK, E., Isik, A., AKSU, S., ÜNER, A., BÜYÜKAŞIK, Y., SAYINALP, N., ... GÖKER, H.(2015). Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms. TURKISH JOURNAL OF HEMATOLOGY , vol.32, no.2, 163-167.
ELİAÇIK, EYLEM Et Al. "Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms," TURKISH JOURNAL OF HEMATOLOGY , vol.32, no.2, 163-167, 2015
ELİAÇIK, EYLEM Et Al. "Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms." TURKISH JOURNAL OF HEMATOLOGY , vol.32, no.2, pp.163-167, 2015
ELİAÇIK, E. Et Al. (2015) . "Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms." TURKISH JOURNAL OF HEMATOLOGY , vol.32, no.2, pp.163-167.
@article{article, author={EYLEM ELİAÇIK Et Al. }, title={Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms}, journal={TURKISH JOURNAL OF HEMATOLOGY}, year=2015, pages={163-167} }